Editas Medicine Inc

Editas Medicine Inc. a clinical stage genome editing company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101 which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301 a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover develop and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine Inc. was incorporated in 2013 and is based in Cambridge Massachusetts.